Nature Research Round Table: HLA Typing Considerations for Human Pluripotent Stem Cell Banking
Dr. David Turner from the Scottish National Blood Transfusion Service discusses immunological considerations around banking of human pluripotent stem cell (hPSC) lines for use in clinical trials. Dr. Turner’s work at the Histocompatibility and Immunogenetics (H&I) Laboratory involves donor-patient HLA-matching for clinical transplants. This presentation and the following Q&A session were moderated by Dr. Joanne Mountford from the University of Glasgow.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Applications of Human Intestinal Organoid Cultures in Drug Discovery
Human intestinal organoids provide a scalable and highly predictive model system for studying the effects of novel therapeutics in vitro. Intestinal organoids contain the relevant cell types that constitute the intestinal epithelium and, as such, can be maintained in various states of proliferation or differentiation. These physiologically relevant models reveal the toxicity of compounds that can not be seen in Caco-2 cells, which are frequently used to model the intestine during drug development programs.
In this webinar, Danny Leung and Dr. Victoria Conlin from STEMCELL Technologies describe, in detail, what intestinal organoids are, how they mimic the immunocytochemistry and morphology of the human gut epithelium, and how to use organoids for drug screening. They also discuss the intestinal organoid assays offered by Contract Assay Services (CAS) at STEMCELL Technologies.
Nature Research Round Table: Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells
Dr. Florian Merkle from the University of Cambridge talks about the implications of quality control during gene editing, in particular genetic variants that arise during routine culture and genetic variants that might have been acquired during the process of gene editing. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
EasySep™小鼠TIL（CD45）正选试剂盒
Nature Research Round Table: HLA Typing Considerations for Human Pluripotent Stem Cell Banking Dr. David Turner from the Scottish National Blood Transfusion Service discusses immunological considerations around banking of human pluripotent stem cell (hPSC) lines for use in clinical trials. Dr. Turner’s work at the Histocompatibility and Immunogenetics (H&I) Laboratory involves donor-patient HLA-matching for clinical transplants. This presentation and the following Q&A session were moderated by Dr. Joanne Mountford from the University of Glasgow.
Applications of Human Intestinal Organoid Cultures in Drug Discovery Human intestinal organoids provide a scalable and highly predictive model system for studying the effects of novel therapeutics in vitro. Intestinal organoids contain the relevant cell types that constitute the intestinal epithelium and, as such, can be maintained in various states of proliferation or differentiation. These physiologically relevant models reveal the toxicity of compounds that can not be seen in Caco-2 cells, which are frequently used to model the intestine during drug development programs.
Nature Research Round Table: Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells Dr. Florian Merkle from the University of Cambridge talks about the implications of quality control during gene editing, in particular genetic variants that arise during routine culture and genetic variants that might have been acquired during the process of gene editing. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.
Treg Isolation Kits: Fast and Versatile Isolation of Human Regulatory T Cells How to get the highest purity Tregs directly from whole blood or PBMC in less time than other methods with STEMCELL's Human Treg Isolation Kits
Performing Total Nucleated Cell Counts with a Hemocytometer Technical tip from our dedicated team of Product and Scientific Support specialists
STEMCELL Technologies Inc. Corporate Overview This video is an overview of STEMCELL Technologies Inc, a privately owned biotechnology company that develops specialty cell culture media
